The DEA’s rejection of rescheduling leaves America at a crossroads. Do we continue allowing an agency with a vested interest in maintaining cannabis prohibition to override scientific evidence on the plant’s medical value? Or do we re-evaluate the necessity of the DEA’s existence altogether?
After five years, two applications, six figures in expenses, and a maze of shifting rules,…
This article was originally published in 2023. From the hash and honey oil of the…
Berner pulled a strain back from the scrap pile, then stood on the Mary Jane…
The independent, Black-owned New Jersey cannabis retailer is opening its second location with a focus…
The summer’s biggest cultural stories are not just about winning. They are about pressure, passion,…
A case of mistaken identity and an experimental psychedelic compound give two best friends telepathic…